Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms.
van Rooij K, Poels S, Bloemers J, Goldstein I, Gerritsen J, van Ham D, van Mameren F, Chivers M, Everaerd W, Koppeschaar H, Olivier B, Tuiten A. van Rooij K, et al. Among authors: goldstein i. J Sex Med. 2013 Mar;10(3):824-37. doi: 10.1111/j.1743-6109.2012.02982.x. Epub 2012 Nov 6. J Sex Med. 2013. PMID: 23130675 Clinical Trial.
Toward personalized sexual medicine (part 1): integrating the "dual control model" into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder.
Bloemers J, van Rooij K, Poels S, Goldstein I, Everaerd W, Koppeschaar H, Chivers M, Gerritsen J, van Ham D, Olivier B, Tuiten A. Bloemers J, et al. Among authors: goldstein i. J Sex Med. 2013 Mar;10(3):791-809. doi: 10.1111/j.1743-6109.2012.02984.x. Epub 2012 Nov 6. J Sex Med. 2013. PMID: 23130782
Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues.
Poels S, Bloemers J, van Rooij K, Goldstein I, Gerritsen J, van Ham D, van Mameren F, Chivers M, Everaerd W, Koppeschaar H, Olivier B, Tuiten A. Poels S, et al. Among authors: goldstein i. J Sex Med. 2013 Mar;10(3):810-23. doi: 10.1111/j.1743-6109.2012.02983.x. Epub 2012 Nov 6. J Sex Med. 2013. PMID: 23130748 Clinical Trial.
Characterization of hypoactive sexual desire disorder (HSDD) in men.
DeRogatis L, Rosen RC, Goldstein I, Werneburg B, Kempthorne-Rawson J, Sand M. DeRogatis L, et al. Among authors: goldstein i. J Sex Med. 2012 Mar;9(3):812-20. doi: 10.1111/j.1743-6109.2011.02592.x. Epub 2012 Jan 12. J Sex Med. 2012. PMID: 22239825
Weight Loss in Women Taking Flibanserin for Hypoactive Sexual Desire Disorder (HSDD): Insights Into Potential Mechanisms.
Simon JA, Kingsberg SA, Goldstein I, Kim NN, Hakim B, Millheiser L. Simon JA, et al. Among authors: goldstein i. Sex Med Rev. 2019 Oct;7(4):575-586. doi: 10.1016/j.sxmr.2019.04.003. Epub 2019 Jun 10. Sex Med Rev. 2019. PMID: 31196764 Review.
METHODS: A literature review was performed using Medline database for relevant publications on the mechanisms of action by which flibanserin may provide weight loss and the links between sexual function and weight management. MAIN OUTCOME MEASURES: Examination of (i) biops …
METHODS: A literature review was performed using Medline database for relevant publications on the mechanisms of action by which flibanserin …
1,398 results